Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCAB NASDAQ:CAPS NASDAQ:CVKD NASDAQ:DARE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCABBioAtla$0.49+9.1%$0.38$0.24▼$2.53$26.75M0.92568,160 shs875,387 shsCAPSCapstone Therapeutics$1.17-0.8%$1.43$0.96▼$16.18$6.81M-0.815.48 million shs103,049 shsCVKDCadrenal Therapeutics$12.87+3.7%$11.91$6.89▼$22.90$26.53M0.9531,307 shs13,854 shsDAREDare Bioscience$2.06+1.5%$2.32$1.83▼$9.19$27.23M1.14218,074 shs72,952 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCABBioAtla+9.06%+9.33%+47.36%+6.96%-73.31%CAPSCapstone Therapeutics-0.85%-4.88%-21.21%-38.42%+116,999,900.00%CVKDCadrenal Therapeutics+3.71%-7.61%+46.08%-11.91%+61.89%DAREDare Bioscience+1.48%+1.98%-13.81%-36.81%-42.78%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCABBioAtla2.3972 of 5 stars3.01.00.00.03.82.50.6CAPSCapstone TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACVKDCadrenal Therapeutics3.4081 of 5 stars3.55.00.00.02.12.50.6DAREDare Bioscience2.1595 of 5 stars3.53.00.00.03.30.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCABBioAtla 2.00Hold$5.00923.54% UpsideCAPSCapstone Therapeutics 0.00N/AN/AN/ACVKDCadrenal Therapeutics 3.00Buy$32.00148.64% UpsideDAREDare Bioscience 3.00Buy$12.00482.52% UpsideCurrent Analyst Ratings BreakdownLatest CAPS, DARE, BCAB, and CVKD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/13/2025BCABBioAtlaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform8/13/2025BCABBioAtlaCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform(Data available from 9/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCABBioAtla$11M2.61N/AN/A($0.29) per share-1.68CAPSCapstone Therapeutics$44.88M0.15N/AN/A$4.70 per share0.25CVKDCadrenal TherapeuticsN/AN/AN/AN/A$2.10 per shareN/ADAREDare Bioscience$10K2,776.88N/AN/A($0.94) per share-2.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCABBioAtla-$69.78M-$1.10N/AN/AN/AN/A-1,177.18%-137.51%11/6/2025 (Estimated)CAPSCapstone Therapeutics-$2.56MN/A0.00∞N/AN/AN/AN/AN/ACVKDCadrenal Therapeutics-$10.65M-$8.88N/AN/AN/AN/A-265.37%-196.38%11/6/2025 (Estimated)DAREDare Bioscience-$4.05M-$2.14N/AN/AN/AN/AN/A-103.70%11/13/2025 (Estimated)Latest CAPS, DARE, BCAB, and CVKD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/15/2025Q2 2025CAPSCapstone TherapeuticsN/A-$0.13N/A-$0.13N/A$12.85 million8/14/2025Q2 2025DAREDare Bioscience-$0.55-$0.45+$0.10-$0.45$0.14 million($0.02) million8/11/2025Q2 2025CVKDCadrenal Therapeutics-$1.60-$1.87-$0.27-$1.87N/AN/A8/7/2025Q2 2025BCABBioAtla-$0.29-$0.31-$0.02-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCABBioAtlaN/AN/AN/AN/AN/ACAPSCapstone TherapeuticsN/AN/AN/AN/AN/ACVKDCadrenal TherapeuticsN/AN/AN/AN/AN/ADAREDare BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCABBioAtlaN/A1.241.24CAPSCapstone Therapeutics0.220.970.41CVKDCadrenal TherapeuticsN/A3.553.55DAREDare BioscienceN/A0.340.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCABBioAtla77.23%CAPSCapstone Therapeutics2.55%CVKDCadrenal Therapeutics7.92%DAREDare Bioscience6.70%Insider OwnershipCompanyInsider OwnershipBCABBioAtla11.22%CAPSCapstone Therapeutics42.80%CVKDCadrenal Therapeutics26.09%DAREDare Bioscience4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCABBioAtla6058.72 million52.13 millionOptionableCAPSCapstone Therapeutics385.58 million3.19 millionN/ACVKDCadrenal Therapeutics42.05 million1.51 millionNot OptionableDAREDare Bioscience3013.48 million12.83 millionNot OptionableCAPS, DARE, BCAB, and CVKD HeadlinesRecent News About These CompaniesDaré Bioscience Engages Market with New PresentationSeptember 3 at 8:27 AM | msn.comDaré Bioscience, Inc. (NASDAQ:DARE) Q2 2025 Earnings Call TranscriptAugust 16, 2025 | msn.comDaré Bioscience Announces Q2 2025 Financial ResultsAugust 15, 2025 | msn.comDaré Bioscience, Inc.: Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 15, 2025 | finanznachrichten.deDaré Bioscience targets Q4 2025 launch for DARE to PLAY Sildenafil cream while advancing dual-path strategyAugust 14, 2025 | msn.comDaré Bioscience, Inc. (DARE) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | seekingalpha.comDare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue EstimatesAugust 14, 2025 | zacks.comDaré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 14, 2025 | globenewswire.comA Preview Of Dare Bioscience's EarningsAugust 13, 2025 | benzinga.comDaré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025August 7, 2025 | globenewswire.comDaré starts push to arouse interest in women’s sexual health drug, tapping app for education driveJuly 30, 2025 | fiercepharma.comFDaré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support ...July 29, 2025 | bakersfield.comBDaré Bioscience, Inc.: Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY Sildenafil CreamJuly 29, 2025 | finanznachrichten.deDaré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil CreamJuly 29, 2025 | finance.yahoo.comDaré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil CreamJuly 29, 2025 | globenewswire.comUPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the BarJuly 21, 2025 | globenewswire.comDaré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the BarJuly 21, 2025 | finance.yahoo.comDaré Bioscience, Inc.: Positive Interim Phase 3 Results Highlight Potential of Ovaprene, Novel Hormone-Free ContraceptiveJuly 15, 2025 | finanznachrichten.deDare Bioscience Analyst Ratings and Price Targets | NASDAQ:DARE | BenzingaJuly 15, 2025 | benzinga.comDaré Bioscience Shares Soar on Data From Phase 3 Contraceptive StudyJuly 15, 2025 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCAPS, DARE, BCAB, and CVKD Company DescriptionsBioAtla NASDAQ:BCAB$0.49 +0.04 (+9.06%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$0.46 -0.02 (-4.81%) As of 09/3/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.Capstone Therapeutics NASDAQ:CAPS$1.17 -0.01 (-0.85%) As of 09/3/2025 04:00 PM EasternCapstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.Cadrenal Therapeutics NASDAQ:CVKD$12.87 +0.46 (+3.71%) Closing price 09/3/2025 03:59 PM EasternExtended Trading$12.50 -0.36 (-2.84%) As of 09/3/2025 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.Dare Bioscience NASDAQ:DARE$2.06 +0.03 (+1.48%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$2.04 -0.02 (-0.97%) As of 09/3/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
